Results presented at the 2025 European Society for Medical Oncology Gastrointestinal Cancers Congress suggested that for patients with ctDNA-positive colorectal cancer after curative surgery, trifluridine/tipiracil as preemptive treatment showed a positive trend toward benefit compared with placebo for extending median DFS and improving ctDNA clearance rate, although statistical significance was not reached ( 82 ).
← all excerpts
Circulating Tumor DNA as a Biomarker in Pancreatic Cancer: Clinical Applications and Challenges.
1
—
—